Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Masahisa Kamikura
Observed name:
M. Kamikura
Institution:
National Cancer Center Hospital
Observed institution:
National Cancer Center Hospital
ORCID:
0009-0005-6267-4128
Observed ORCID:
0009-0005-6267-4128
OpenAlex ID:
A5027422615
Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510)
2024
·
Tadaaki Nishikawa
, Shigeki Kakunaga
, et al.
·
Cancer
·
18
Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
·
Clinical Cancer Research
·
13
PDF
Real-world characterization of patients with advanced or metastatic liposarcoma, including dedifferentiated liposarcoma, in Japan in the MASTER KEY project
2026
·
Hitomi Sumiyoshi Okuma
, Kenji Tsuchihashi
, et al.
·
Japanese Journal of Clinical Oncology
Integrated analysis of two phase 2 trials of nivolumab in metastatic rare solid cancer with dMMR or pMMR (MASTER KEY sub-studies: ROCK and ROLL trial).
2024
·
Masashi Kanai
, Hitomi Sumiyoshi Okuma
, et al.
·
Journal of Clinical Oncology
PDF
Supplementary Figure S6 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
PDF
Supplementary Figure S1 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Supplementary Figure S5 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
PDF
Supplementary Figure S3 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Supplementary Table S2 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Supplementary Table S3 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Supplementary Table S1 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Supplementary Figure S4 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Supplementary Figure S2 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Data from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Supplementary Table S4 from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
Data from Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
2023
·
Hitomi S. Okuma
, Keisuke Watanabe
, et al.
1521O A phase II biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, an ultra-rare cancer with highly life-threatening unmet medical needs (NCCH1806/MK004)
2021
·
Y. Kojima
, T. Shimizu
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
17
Citation count:
31
H-index:
2
I10-index:
2
Year
Topic
Type